

Applicant : Lee Mizzen *et al.*  
Serial No. : 08/977,787  
Filed : November 25, 1997  
Page : 2

Attorney's Docket No.: 12071-011002

<sup>58</sup> 58. (Amended) The fusion protein of claim <sup>53</sup> 54, wherein the fusion protein is encoded by plasmid pET65MP/NP-B or plasmid pET65MP/NP-D.

<sup>59</sup> 59. (Amended) The fusion protein of claim <sup>53</sup> 54, wherein the antigen includes a CTL epitope.

<sup>60</sup> 60. (Amended) A fusion protein comprising an antigen of an influenza virus, or an antigenic portion thereof, and a bacterial stress protein, or a portion thereof, wherein the fusion protein induces an immune response against the antigen in a mammal to whom the fusion protein is administered.

<sup>61</sup> 61. (Amended) The fusion protein of claim <sup>60</sup> 60, wherein the bacterial stress protein is a mycobacterial stress protein.

<sup>62</sup> 62. (Amended) A composition comprising the fusion protein of claim <sup>53</sup> 54 and a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

<sup>63</sup> 63. (Amended) A method of inducing an immune response against an antigen of an influenza virus, the method comprising administering the fusion protein of claim <sup>53</sup> 54 to a vertebrate in an amount effective to induce an immune response against the antigen.

<sup>64</sup> 64. (Amended) The method of claim <sup>63</sup> 63, wherein the fusion protein is administered in combination with a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

<sup>65</sup> 65. (Amended) A method of inducing an immune response against an antigen of the influenza virus, the method comprising administering the fusion protein of claim <sup>53</sup> 54 to a vertebrate in an amount effective to induce an immune response against the antigen.

<sup>66</sup> 66. (Amended) The method of claim <sup>65</sup> 65, wherein the fusion protein is administered in combination with a pharmaceutically acceptable excipient, carrier, diluent, or vehicle. --

Applicant : Lee Mizzen *et al.*  
Serial No. : 08/977,787  
Filed : November 25, 1997  
Page : 3

Attorney's Docket No.: 12071-011002

Add claims 68-87.

4  
68. The fusion protein of claim <sup>53</sup>54, wherein the immune response is a cell mediated immune response.

69. The fusion protein of claim <sup>67</sup>68, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

70. The fusion protein of claim <sup>69</sup>62, wherein the stress protein is hsp65.

71. The fusion protein of claim <sup>69</sup>62, wherein the stress protein is hsp71.

72. The fusion protein of claim <sup>53</sup>54, wherein the stress protein is an Hsp100-200, an Hsp100, an Hsp90, Lon, an Hsp70, an Hsp60, TF55, an Hsp40, an FKBP, a cyclophilin, an Hsp20-30, ClpP, GrpE, Hsp10, ubiquitin, calnexin, or a protein disulfide isomerase.

73. The method of claim <sup>63</sup>64, wherein the immune response is a cell mediated immune response.

74. The method of claim <sup>72</sup>73, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

75. A fusion protein comprising a human papillomavirus (HPV) antigen, or an antigenic portion thereof, and a stress protein or a portion thereof, wherein the fusion protein induces an immune response to the HPV antigen in a mammal to whom the fusion protein is administered.

76. The fusion protein of claim <sup>74</sup>75, wherein the HPV antigen is an E6 protein.

77. The fusion protein of claim <sup>74</sup>75, wherein the HPV antigen is an E7 protein.

Applicant : Lee Mizzen *et al.*  
Serial No. : 08/977,787  
Filed : November 25, 1997  
Page : 4

Attorney's Docket No.: 12071-011002

- 77  
78. The fusion protein of claim <sup>74</sup>75, wherein the HPV antigen includes a CTL epitope.
- 78  
79. The fusion protein of claim <sup>74</sup>75, wherein the stress protein is a bacterial stress protein.
- 79  
80. The fusion protein of claim <sup>74</sup>75, wherein the stress protein is an Hsp100-200, an Hsp100, an Hsp90, Lon, an Hsp70, an Hsp60, TF55, an Hsp40, an FKBP, a cyclophilin, an Hsp20-30, ClpP, GrpE, Hsp10, ubiquitin, calnexin, or a protein disulfide isomerase.
- 80  
81. The fusion protein of claim <sup>74</sup>75, wherein the stress protein is a mycobacterial stress protein.
- 81  
82. The fusion protein of claim <sup>80</sup>81, wherein the stress protein is hsp65.
- 82  
83. The fusion protein of claim <sup>80</sup>81, wherein the stress protein is hsp71.
- 83  
84. The fusion protein of claim <sup>74</sup>75, wherein the immune response is a cell mediated immune response.
- 84  
85. The fusion protein of claim <sup>83</sup>84, wherein the cell mediated immune response is a cell mediated cytolytic immune response.
- 85  
86. A composition comprising the fusion protein of claim 75 and a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.
- 86  
87. The fusion protein of claim <sup>70</sup>77, wherein the stress protein is mycobacterial Hsp65.--